Scarica l'app Stockscreener
0.2498
20.10%
0.0418
Dopo l'orario di chiusura:
.24
-0.0098
-3.92%
Precedente Chiudi:
$0.208
Aprire:
$0.2087
Volume 24 ore:
10.66M
Relative Volume:
1.27
Capitalizzazione di mercato:
$6.36M
Reddito:
$359.70K
Utile/perdita netta:
$-14.24M
Rapporto P/E:
-0.1525
EPS:
-1.6376
Flusso di cassa netto:
$-10.91M
1 W Prestazione:
+36.06%
1M Prestazione:
+8.66%
6M Prestazione:
-77.29%
1 anno Prestazione:
-84.95%
Intervallo 1D:
$0.2079
$0.2899
Intervallo di 1 settimana:
$0.1593
$0.2899
Portata 52W:
$0.1593
$2.045
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Nome
Biorestorative Therapies Inc
Settore
Industria
Telefono
(631) 760-8100
Indirizzo
40 MARCUS DRIVE, MELVILLE
Compare BRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
0.2498 | 5.30M | 359.70K | -14.24M | -10.91M | -1.6376 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biorestorative Therapies Inc Borsa (BRTX) Ultime notizie
Biorestorative Therapies says topline phase 2 data for BRTX-100 expected in Q2 2027 - marketscreener.com
Biorestorative Therapies Says Topline Phase 2 Data For BRTX-100 Expected In Q2 2027 - TradingView
BioRestorative Therapies Completes Patient Dosing in Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease - Quiver Quantitative
Stem cell back pain shot finishes Phase 2, topline data due 2027 - Stock Titan
BRTX Should I Buy - Intellectia AI
BioRestorative Therapies (BRTX) Surges 13.66% as Stock Tests Key Resistance at $0.20Corrective Wave - Newser
What makes Biorestorative Therapies (BRTX) a new buy stock - MSN
Biorestorative Therapies, Inc. (BRTX) reports Q1 loss, misses revenue estimates - MSN
Auctus Fund (BRTX) discloses 2.7M-share, 9.9% position including warrants - Stock Titan
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
MSN Money - MSN
Certain Series B Preferred Stock of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Warrants of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Certain Options of BioRestorative Therapies, Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2026. - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
BioRestorative Therapies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioRestorative Therapies, Inc. 1Q 2026: Revenue $23.2K, EPS $(0.12) — 10-Q Summary - TradingView
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioRestorative Therapies (BRTX) Q1 2026 loss, cash burn and Nasdaq bid-price risk - Stock Titan
BioRestorative presents data on stem cell-derived exosomes By Investing.com - Investing.com India
BioRestorative presents data on stem cell-derived exosomes - Investing.com UK
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals - The Manila Times
Biorestorative Therapies Presents New Preclinical Data on Source-Specific Exosome Functionality and Commercial Applications in Biocosmeceuticals - marketscreener.com
TradingKey - TradingKey
BioRestorative Therapies Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - Orthopedics This Week
Biorestorative Therapies' BRTX-100 shows sustained pain & functional improvements in chronic lumbar disc disease - marketscreener.com
BioRestorative Therapies’ BRTX-100 Phase 2 Data Shows Continued Pain Reduction in Lumbar Disc Disease Patients - geneonline.com
BioRestorative Therapies announced that its 52-week clinical study cohort has been expanded to 25 patients. - Bitget
Back pain stem cell study shows 52% had 50% pain and function gains - Stock Titan
BRTX Stock Price, Quote & Chart | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
BioRestorative Therapies Boosts Executive Compensation and Equity Incentives - TipRanks
Biorestorative Therapies | 8-K: Current report - Moomoo
BioRestorative Therapies awards cash bonuses to CEO Lance Alstodt, VP Francisco Silva and CFO Robert Kristal - TradingView
BioRestorative (NASDAQ: BRTX) details 2025 executive pay and bonuses - Stock Titan
Biorestorative Therapies | EFFECT: Others - Moomoo
Biorestorative Therapies | 424B3: Prospectus - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) registers 15.29M warrant shares - Stock Titan
BioRestorative to present clinical, preclinical data at ISCT - Investing.com UK
BioRestorative to present clinical, preclinical data at ISCT By Investing.com - Investing.com Nigeria
BioRestorative Therapies Presents New Data on MSC-Derived Programs at ISCT 2026 Annual Meeting - Quiver Quantitative
BioRestorative brings two programs to Dublin, including Phase 2 spine trial data - Stock Titan
Biorestorative Therapies Inc Presents New Data at ISCT 2026 Highlighting Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Biocosmeceutical Platform - marketscreener.com
Biorestorative Therapies, Inc. (BRTX) reports Q4 loss, lags revenue estimates - MSN
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform - The Manila Times
[EFFECT] BioRestorative Therapies, Inc. SEC Filing - Stock Titan
Here's why Biorestorative Therapies (BRTX) looks ripe for bottom fishing - MSN
Biorestorative Therapies | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
BioRestorative Therapies (NASDAQ: BRTX) files S-1/A amendment; counsel opinion added - Stock Titan
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing - Yahoo! Finance Canada
Biorestorative Therapies Inc Azioni (BRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):